NEW YORK (GenomeWeb) – Belgian personalized cancer firm OncoDNA said today it has been awarded a contract to conduct testing and analysis for the Breast International Group (BIG), a Brussels non-profit that funds breast cancer research.

Under the multi-year contract, OncoDNA will perform its OncoDEEP Clinical Plus test on primary and metastatic tumor and blood samples from BIG's AURORA breast cancer clinical research program, which launched on April 15.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.